Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798464 | 0.72 | ALDH1A1 (0.33) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL19258711 | 0.72 | ALDH1A1 (0.46) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL12528005 | 0.71 | ACLY (0.58) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL23772237 | 0.69 | CYP2C19 (0.46) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL12524010 | 0.69 | ACLY (0.43) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL18798915 | 0.69 | ACLY (0.43) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL12458905 | 0.68 | ACLY (0.39) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL18798923 | 0.67 | ACLY (0.38) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL12458904 | 0.62 | ACLY (0.38) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL22421672 | 0.61 | CYP2C19 (0.43) | ACLYCPT2ALDH1A1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH | 2017-08-17 | — | — | US | disclosed |
| US-9636352-B2 | Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20120238521-A1 | Compositions and Methods for the Treatment of Musculoskeletal Related Diseases and Disorders Using Metal Ion-Citrate Analog Complexes | The Charlotte-Mecklenbury Hospital Authority d/b/a Carolinas Medical Center (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES | CS, ACLY, CA5A | ACLY 2/4885CPT2 288/4885ALDH1A1 1294/4885 |
| US-20120238521-A1 | Compositions and Methods for the Treatment of Musculoskeletal Related Diseases and Disorders Using Metal Ion-Citrate Analog Complexes | CS, ACLY, CA5A | ACLY 2/4885CPT2 288/4885ALDH1A1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.